Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Integrated Dna Technologies Inc. has 8 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 7 distinct examiners and 5 distinct art units. The busiest examiner, HUTSON, RICHARD G, is managing 2 busiest examiner pending actions.
The 8 pending office actions are distributed such that 7 distinct examiners are involved, meaning at least one examiner is handling multiple cases. Specifically, HUTSON, RICHARD G is responsible for 2 busiest examiner pending actions. The 5 distinct art units involved indicate that the Biotechnology & Pharmaceuticals portfolio is being examined across several different technical departments. With 8 pending office actions, the workload is relatively high, requiring attention to the specific preferences of 7 distinct examiners. The concentration of 2 busiest examiner pending actions under HUTSON, RICHARD G makes this examiner a key figure in the current prosecution cycle for the 8 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (12%) |
| Multi-statute (no §101) | 7 (88%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTSON, RICHARD G | 2 | 65.1% | +53.1% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.7% | +31.8% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
| HORLICK, KENNETH R | 1 | 78.9% | +15.3% |
| RYAN, DOUGLAS CHARLES | 1 | 39.2% | +47.6% |
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
| OYEYEMI, OLAYINKA A | 1 | 60.4% | +46.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17208286 | DNA POLYMERASE MUTANTS HAVING ENHANCED TEMPLATE DISCRIMINATION ACTIVITY | HUTSON, RICHARD G | 9d |
| 18647516 | EUBACTERIUM RECTALE CAS12A MUTANTS | BERKE-SCHLESSEL, DAVID W | — |
| 18613719 | USE OF A 53BP1 BINDING HUMAN UBIQUITIN VARIANT TO IMPROVE RATES OF HDR IN MULTIPLE CELL TYPES | WILSON, MICHAEL C | — |
| 18417992 | METHODS FOR VARIANT DETECTION | HORLICK, KENNETH R | — |
| 18404826 | CRISPR-BASED COMPOSITIONS AND METHODS OF USE | RYAN, DOUGLAS CHARLES | — |
| 18316454 | USE OF UNIQUE MOLECULAR IDENTIFIERS FOR IMPROVED ACCURACY OF LONG READ SEQUENCING AND CHARACTERIZATION OF CRISPR EDITING | GRAY, JESSICA | — |
| 18176091 | C-TERMINAL PEPTIDE EXTENSIONS WITH INCREASED ACTIVITY | HUTSON, RICHARD G | — |
| 18102198 | Tm-ENHANCED BLOCKING OLIGONUCLEOTIDES AND BAITS FOR IMPROVED TARGET ENRICHMENT AND REDUCED OFF-TARGET SELECTION | OYEYEMI, OLAYINKA A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17208286 | DNA POLYMERASE MUTANTS HAVING ENHANCED TEMPLATE DISCRIMINATION ACTIVITY | HUTSON, RICHARD G | 9d |
| 18647516 | EUBACTERIUM RECTALE CAS12A MUTANTS | BERKE-SCHLESSEL, DAVID W | — |
| 18613719 | USE OF A 53BP1 BINDING HUMAN UBIQUITIN VARIANT TO IMPROVE RATES OF HDR IN MULTIPLE CELL TYPES | WILSON, MICHAEL C | — |
| 18417992 | METHODS FOR VARIANT DETECTION | HORLICK, KENNETH R | — |
| 18404826 | CRISPR-BASED COMPOSITIONS AND METHODS OF USE | RYAN, DOUGLAS CHARLES | — |
| 18176091 | C-TERMINAL PEPTIDE EXTENSIONS WITH INCREASED ACTIVITY | HUTSON, RICHARD G | — |
| 18102198 | Tm-ENHANCED BLOCKING OLIGONUCLEOTIDES AND BAITS FOR IMPROVED TARGET ENRICHMENT AND REDUCED OFF-TARGET SELECTION | OYEYEMI, OLAYINKA A | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1651 | 1 |
| 1635 | 1 |
| 1682 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18647516 | EUBACTERIUM RECTALE CAS12A MUTANTS | BERKE-SCHLESSEL, DAVID W | 1651 | §102§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18613719 | USE OF A 53BP1 BINDING HUMAN UBIQUITIN VARIANT TO IMPROVE RATES OF HDR IN MULTIPLE CELL TYPES | WILSON, MICHAEL C | — | §102§103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
| 18417992 | METHODS FOR VARIANT DETECTION | HORLICK, KENNETH R | — | §102§103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18404826 | CRISPR-BASED COMPOSITIONS AND METHODS OF USE | RYAN, DOUGLAS CHARLES | 1635 | §103§112 | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18316454 | USE OF UNIQUE MOLECULAR IDENTIFIERS FOR IMPROVED ACCURACY OF LONG READ SEQUENCING AND CHARACTERIZATION OF CRISPR EDITING | GRAY, JESSICA | 1682 | §103 | Non-Final OA | — | Pending | May 12, 2023 |
| 18176091 | C-TERMINAL PEPTIDE EXTENSIONS WITH INCREASED ACTIVITY | HUTSON, RICHARD G | 1652 | §102§112 | Final Rejection | — | Pending | Feb 28, 2023 |
| 18102198 | Tm-ENHANCED BLOCKING OLIGONUCLEOTIDES AND BAITS FOR IMPROVED TARGET ENRICHMENT AND REDUCED OFF-TARGET SELECTION | OYEYEMI, OLAYINKA A | 1681 | §102§103 | Non-Final OA | — | Pending | Jan 27, 2023 |
| 17208286 | DNA POLYMERASE MUTANTS HAVING ENHANCED TEMPLATE DISCRIMINATION ACTIVITY | HUTSON, RICHARD G | 1652 | §103§112 | Non-Final OA | 9d | Pending | Mar 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial